buyers starting to build been watching this for some time, the data really is great news. It was reported in a GP magazine yesterday, pity I recieved it only last night. I have made the plunge into this one, very under the radar. They talk about a 260 million dollar market but what they DON"T discuss is the fact that the present test, CEA, is so useless that it is recommended not to use it for screening. It causes more distress than it's worth.
With a more sensitive and specific test, you will see this test being much more recommended and promoted, and I see the potential for this market being expanded tenfold or more. If there's one thing GP's like to do is to order tests. Prostate tests are way over-ordered when the test has low sensitivity and specificity and is not recommended by most medical bodies as a general screening tool. However, it is likely that this ovarian cancer test now meets the criteria for a screening test in terms of specificity and sensitivity.
The fact that it is not a drug means it can get into production and sales really quickly. Anyone know about potential sales internationally?
As a practicing GP, I am happy to try and answer any questions that you post on this.
Add to My Watchlist
What is My Watchlist?